1-8 of 8
Dimitra Tsavachidou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A2: A Study of the effects of MDV3100 in the tumor microenvironment of bone metastatic castrate resistant prostate cancer (bmCRPC)

Eleni Efstathiou, Patricia Troncoso, James Mohler, Christopher J. Logothetis, Mark Titus, Dimitra Tsavachidou, Sijin Wen, Anh Hoang, Robynne Ashe, Maria Karlou, Craig Berman
Journal: Cancer Research
Cancer Res (2012) 72 (4_Supplement): A2.
https://doi.org/10.1158/1538-7445.PRCA2012-A2
Published: 09 May 2013
View article titled, Abstract A2: A Study of the effects of MDV3100 in the tumor microenvironment of bone metastatic castrate resistant prostate cancer (bmCRPC)
Journal Articles

Abstract 1265: Sustained PI3-kinase signaling is mediated by ICOS, not CD28, for anti-tumor T-cell responses elicited by anti-CTLA-4.

Hong Chen, Tihui Fu, Dimitra Tsavachidou, Sijin Wen, Derek Ng Tang, Qiuming He, Jing Jing Sun, Padmanee Sharma
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 1265.
https://doi.org/10.1158/1538-7445.AM2013-1265
Published: 15 April 2013
View article titled, Abstract 1265: Sustained PI3-kinase signaling is mediated by ICOS, not CD28, for anti-tumor T-cell responses elicited by anti-CTLA-4.
Journal Articles

Abstract 1278: Determining the proteomic changes that define progressor and non-progressor clear cell renal cell carcinoma

Ghada Kurban, Dimitra Tsavachidou, Brenda Gallie, Andrew Evans, Antonio Finelli, Eric Jonasch, Michael Jewett
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1278.
https://doi.org/10.1158/1538-7445.AM2012-1278
Published: 15 April 2012
View article titled, Abstract 1278: Determining the proteomic changes that define progressor and non-progressor clear cell renal cell carcinoma
Journal Articles

Abstract 2696: Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100

Eleni Efstathiou, Mark Titus, Dimitra Tsavachidou, Sijin Wen, Anh Hoang, Robynne Ashe, Maria Karlou, Craig Berman, Patricia Troncoso, James Mohler, Christopher J. Logothetis
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2696.
https://doi.org/10.1158/1538-7445.AM2012-2696
Published: 15 April 2012
View article titled, Abstract 2696: Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100
Journal Articles

Abstract 4612: Cell-type dependent responses to selenium and knockdown of SBP2

Jin Li, Milind B. Suraokar, Dimitra Tsavachidou, David G. Menter, Jeri Kim
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4612.
https://doi.org/10.1158/1538-7445.AM2011-4612
Published: 15 April 2011
View article titled, Abstract 4612: Cell-type dependent responses to selenium and knockdown of SBP2
Journal Articles

Abstract LB-421: Characterization of castrate resistant prostate cancer treated with abiraterone acetate and prednisone

Eleni Efstathiou, Mark Titus, Dimitra Tsavachidou, Vassiliki Tzelepi, Sijin Wen, Anh Hoang, Arturo Molina, Nicole Chieffo, Lisa A. Smith, BS RN Smith, Maria Karlou Karlou, Patricia Troncoso, Christopher J. Logothetis
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): LB-421.
https://doi.org/10.1158/1538-7445.AM2011-LB-421
Published: 15 April 2011
View article titled, Abstract LB-421: Characterization of castrate resistant prostate cancer treated with abiraterone acetate and prednisone
Journal Articles

SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant

Dimitra Tsavachidou, Mathew L. Coleman, Galene Athanasiadis, Shuixing Li, Jonathan D. Licht, Michael F. Olson, Barbara L. Weber
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5556–5559.
https://doi.org/10.1158/0008-5472.CAN-04-1669
Published: 16 August 2004
View article titled, SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type <em>BRAF</em> but Not with the V599E Mutant
Open the PDF for SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type <em>BRAF</em> but Not with the V599E Mutant in another window
Journal Articles

Role of the BRAF mutation in melanoma. A global gene expression profiling approach

Dimitra Tsavachidou, Mathew L. Coleman, Michael F. Olson, Barbara L. Weber
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 375.
Published: 01 April 2004
View article titled, Role of the BRAF mutation in melanoma. A global gene expression profiling approach